REFERENCES

1. Barciszewska AM, Gurda D, Głodowicz P, Nowak S, Naskręt-Barciszewska MZ. A new epigenetic mechanism of temozolomide action in glioma cells. PLoS One 2015;10:e0136669.

2. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.

3. Jalbert LE, Neill E, Phillips JJ, Lupo JM, Olson MP, et al. Magnetic resonance analysis of malignant transformation in recurrent glioma. Neuro Oncol 2016;18:1169-79.

4. Rempel SA, Dudas S, Ge S, Gutiérrez JA. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 2000;6:102-11.

5. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12:259-66.

6. Peak SJ, Levin VA. Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res 2010;2:97-104.

7. Shao R, Taylor SL, Oh DS, Schwartz LM. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization. Oncotarget 2015;6:40507-18.

8. Gil-Gil MJ, Mesia C, Rey M, Bruna J. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 2013;7:123-35.

9. Nagane M. Dose-dense temozolomide: is it still promising? Neurol Med Chir (Tokyo) 2015;55:38-49.

10. Xu H, Rahimpour S, Nesvick CL, Zhang X, Ma JY, et al. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy. Oncotarget 2015;6:11882-93.

11. Martínez-González A, Calvo GF, Pérez Romasanta LA, Pérez-García VM. Hypoxic cell waves around necrotic cores in glioblastoma: a biomathematical model and its therapeutic implications. Bull Math Biol 2012;74:2875-96.

12. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006;70:1469-80.

13. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.

14. Koukourakis GV, Kouloulias V, Zacharias G, Papadimitriou C, Pantelakos P, et al. Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules 2009;14:1561-77.

15. Takano S, Ishikawa E, Nakai K, Matsuda M, Masumoto T, et al. Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial. Onco Targets Ther 2014;7:1551-62.

16. Poulsen HS, Urup T, Michaelsen SR, Staberg M, Villingshøj M, Lassen U. The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Manag Res 2014;6:373-87.

17. Gatson NN, Chiocca EA, Kaur B. Anti-angiogenic gene therapy in the treatment of malignant gliomas. Neurosci Lett 2012;527:62-70.

18. Balañá C, Etxaniz O, Bugés C, Martínez A. Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error? Clin Transl Oncol 2011;13:209-10.

19. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.

20. Pérez-Beteta J, Martínez-González A, Molina D, Amo-Salas M, Luque B, et al. Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study. Eur Radiol 2017;27:1096-104.

21. Molina D, Pérez-Beteta J, Luque B, Arregui E, Calvo M, et al. Tumour heterogeneity in glioblastoma assessed by MRI texture analysis: a potential marker of survival. Br J Radiol 2016;89:20160242.

22. Molina D, Pérez-Beteta J, Martínez-González A, Sepúlveda JM, Peralta S, et al. Geometrical measures obtained from pretreatment postcontrast T1 weighted MRIs predict survival benefits from bevacizumab in glioblastoma patients. PLoS One 2016;11:e0161484.

23. Manneh Kopp RA, Sepúlveda-Sánchez JM, Ruano Y, Toldos O, Peérez Núñez A, et al. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab. Clin Transl Oncol 2019;21:1413-23.

24. Que Y, Qiu H, Li Y, Chen Y, Xiao W, et al. Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma. BMC Cancer 2015;15:648.

25. Feng Z, Wen H, Bi R, Ju X, Chen X, et al. Preoperative neutrophil-to-lymphocyte ratio as a predictive and prognostic factor for high-grade serous ovarian cancer. PLoS One 2016;11:e0156101.

26. Zhou X, Du Y, Huang Z, Xu J, Qiu T, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One 2014;9:e101119.

27. D’Emic N, Engelman A, Molitoris J, Hanlon A, Sharma NK, et al. Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy. J Gastrointest Oncol 2016;7:269-77.

28. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014;23:1204-12.

29. Passardi A, Scarpi E, Cavanna L, Dall’Agata M, Tassinari D, et al. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget 2016;7:33210-9.

30. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124.

31. Alexiou GA, Vartholomatos E, Voulgaris S. Prognostic value of neutrophil-to-lymphocyte ratio in patients with glioblastoma. J Neurooncol 2013;115:521-2.

32. McNamara MG, Lwin Z, Jiang H, Templeton AJ, Zadeh G, et al. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. J Neurooncol 2014;117:147-52.

33. Han S, Liu Y, Li Q, Li Z, Hou H, et al. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer 2015;15:617.

34. Audureau E, Chivet A, Ursu R, Corns R, Metellus P, et al. Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model. J Neurooncol 2018;136:565-76.

35. Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangère V, et al. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma. Oncotarget 2016;7:70948-58.

36. Vaios EJ, Winter SF, Muzikansky A, Nahed BV, Dietrich J. Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma. Neuro-Oncology Advances 2020;2:vdaa031.

37. Bogdanska MU, Bodnar M, Piotrowska MJ, Murek M, Schucht P, et al. A mathematical model describes the malignant transformation of low grade gliomas: Prognostic implications. PLoS One 2017;12:e0179999.